Advanced search
Publication Cover
Nordic Journal of Psychiatry Volume 54, 2000 - Issue 6
Submit an article Journal homepage
12
Views
8
CrossRef citations to date
0
Altmetric
Research Article

a2-Adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson disease and depression

Dag Årsland, Jan P. Larsen, Neh Geok Lim, Lene Wermuth, Per Bech Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital, Stavanger, Norway; Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway; Department of Neurology, Sønderborg Hospital, Sønderborg, Denmark; Psychiatric Institute, Fredriksborg General Hospital, Hillerød, Denmark
Pages 411-415 | Published online: 12 Jul 2009

REFERENCES

  • Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occur-rence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53:17 5–9.
  • Starkstein SE, Mayberg HS, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairment in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:37 7–82.
  • Miller E, Berrios GE, Politynska BE. Caring for someone with Parkinson's disease: factors that contribute to distress. Int J Ger Psychiatry 1996;11:26 3–8.
  • Mayeux R, Stern Y, Williams JB, Cote L, Frantz A, Dyren-furth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986;143:75 6–9.
  • Klaassen T, Verhey FRJ, Sneijders HJM, Rozendaal N, de Vet HCW, van Praag HM. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995;7:28 1–6.
  • Hauser RA, Zesiewicz TA. Sertraline for the treatment of de-pression in Parkinson's disease. Mov Dis 1997;12:75 6–9.
  • Wermuth L, Sorensen PS, Timm S, Christensen B, Utzon NP, Bons J, et al. Citalopram for depression in idiopathic Parkin-son's disease. A placebo-controlled trial. Nord J Psychiatry 1998;52:163–9.
  • Andersen J, Aabro E, Gulman N, Hjelmested A, Pedersen HE. Antidepressant treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand 1980;62:21 0–
  • Brogden RN, Heel RC, Avery GS. Mianserin: a review of its pharmacological properies and therapeutic efficacy in depressive illness. Drugs 1978;16:27 3–301.
  • Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998;31:4 8–54.
  • Brefel-Courben C, Thalamas C, Paul HPS, Senard J-M, Mon-tastruc J-L, Rascol 0. ot2-adrenoceptor antagonists. A new ap-proach in Parkinson's disease. CNS Drugs 1998;10: 189–207.
  • Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Dis 1995;10:54 1–9.
  • Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.
  • Snaith RP, Harrop FM, Teale C. Grade scores on the Mont-gomery Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry 1986;148:599–601.
  • Larsen JP, Dupont E, Tandberg E. The clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;84:242–51.
  • Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, editors. Recent de-velopment in Parkinson's disease. Florham Park (NJ): Macmil-lan Health Care Information; 1987. p. 153–163.
  • Folstein MF, Folstein SE, McHugh PR. Mini-Mental State": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12: 189–95.
  • Bech P. The Bech, Hamilton and Zung scales for mood disor-ders: screening and listening. 2nd ed. Berlin: Springer Verlag; 1996.
  • Lingjazrde 0, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-ef-fects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;7 6 Supp1:334.
  • Karlsen KH, Larsen JP, Tandberg E, Mazland JG. Quality of life measurements in patients with Parkinson's disease. A com-munity-based study. Eur J Neurol 1998;54:443–50.
  • Leo RJ. Movement disorders associated with the serotonin se-lective reuptake inhibitors. J Clin Psychiatry 1996;57:449–54.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.